In 2001, researchers studying the brains of Alzheimer's patients discovered something unexpected. Encoded within mitochondrial DNA — not the nuclear genome, where most human genes reside — was a short sequence that, when expressed as a peptide, protected neurons from the cell death characteristic of Alzheimer's pathology. They called it Humanin, because it appeared to preserve human life at the cellular level.
Humanin is a 21-amino acid peptide encoded within the 16S ribosomal RNA gene of mitochondrial DNA — an unusual location that suggests it may have evolutionary origins in the ancestral bacterial lineage from which mitochondria descended. This mitochondrial origin makes it part of a recently discovered family called mitochondria-derived peptides (MDPs), which includes MOTS-c and the SHLP family.
The discovery that the mitochondrial genome encodes signalling peptides was not anticipated. It has opened an entirely new area of research — one that suggests mitochondria are not merely energy-producing organelles but active communicators in cellular and systemic signalling.
Humanin's documented functions are surprisingly broad for a 21-amino acid peptide. Neuroprotective effects are the most studied — it inhibits neuronal apoptosis triggered by multiple Alzheimer's-related insults including amyloid-beta toxicity. It activates several protective signalling pathways including STAT3, MAPK and PI3K-Akt.
Beyond the brain: Humanin has shown cardioprotective effects in animal models of cardiac injury, reducing infarct size and improving cardiac function post-ischemia. It also has demonstrated insulin-sensitising effects — improving glucose uptake and reducing hepatic glucose production — and anti-inflammatory properties through modulation of inflammatory cytokine expression.
A particularly interesting finding: Humanin appears to regulate apoptosis in a tissue-specific and context-specific way. It protects non-cancerous cells from apoptosis while appearing to have pro-apoptotic effects in certain cancer cell lines — a selectivity that researchers are actively investigating.
Serum Humanin levels decline with age. Studies in humans show significantly lower circulating Humanin in older adults compared to younger controls, and lower levels in Alzheimer's patients compared to age-matched healthy controls.
Children of centenarians — people whose parents lived to 100 — have been found to have higher Humanin levels than age-matched controls without long-lived parents. This is one of several pieces of evidence suggesting that Humanin levels may be partly heritable and may contribute to familial longevity patterns.
The research focus on Humanin has expanded significantly since its discovery. Current areas of investigation include: Alzheimer's disease prevention and treatment, cardiovascular protection, metabolic syndrome, and as a biomarker of mitochondrial function and biological ageing.
A 2022 study found that Humanin levels were inversely correlated with biological age as measured by epigenetic clocks — people with higher Humanin appeared biologically younger by epigenetic measures, independent of chronological age. This correlation does not establish causation but adds to the cumulative evidence that Humanin is connected to something fundamental in the ageing process.
Recombinant Humanin analogues with improved stability and potency are under development. HNG (Humanin with glycine substitution at position 14) shows significantly enhanced activity in most model systems and is the form used in most current research.
Humanin represents a category of research that is both genuinely exciting and genuinely early. The mechanistic basis for its effects is increasingly well understood. The animal data is consistent and replicated across multiple laboratories. The human correlational data is suggestive.
What is missing is the human intervention data — does administering Humanin in humans produce the protective effects seen in animals? That research is ongoing but not yet complete. For now, Humanin sits in the same category as many of the most interesting compounds in longevity science: mechanistically compelling, preclinically strong, clinically promising but unproven.
Enter your email and we'll notify you when we publish something new. Free. No Pep IQ account required. Unsubscribe anytime.
Complete reference entries, protocol guidance and blood work calendars for the compounds in active use.